knowledge -WSS

knowledge

author：entertainment 2025-10-01 23:03:53 - browse：67

ASH19 CAR-T — Victor Segura Ibarra and Rita Serda, Ph.D., NCI, NIH

The Food and Drug Administration on Wednesday approved a futuristic new approach to treating cancer, clearing a Novartis therapy that has produced unprecedented results in patients with a rare and deadly cancer. The price tag: $475,000 for a course of treatment.

That sounds staggering to many patients — but it’s far less than analysts expected.

The therapy, called a CAR-T, is made by harvesting patients’ white blood cells and rewiring them to home in on tumors. Novartis’s product is the first CAR-T therapy to come before the FDA, leading a pack of novel treatments that promise to change the standard of care for certain aggressive blood cancers.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Medicare proposal to cover medical devices draws a mixed reaction
Next article： Elevance, SCAN deals highlight health insurer acquisition scrutiny

WSS

Elevance, SCAN deals highlight health insurer acquisition scrutiny

FDA warns medical device makers about rise in fabricated data

FDA warns medical device makers about rise in fabricated data

Peter Marks talks Operation Warp Speed for Rare Diseases

MD Anderson's Padmanee Sharma responds to research credit suit

Female surgeons have lower rates of long

leisure time

knowledge

hotspot

Guidelines to prevent youth baseball injuries need more muscle

What the Wegovy shortage looks like for doctors — and for patients

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Kidney disease boosts cardiac arrest risk for Hispanics, Latinos

Sports medicine is finally prioritizing gender equality

Female surgeons have lower rates of long

Trump demands the U.S. pay no more for drugs than other countries … again

Reporting on presidential health from Reagan to Trump and Biden

United colonoscopy coverage change 'may cost lives,' doctors say

WATCH: Why do our ears pop?

focus

A revolution in caring for preterm infants

Peter Marks talks Operation Warp Speed for Rare Diseases

Female surgeons have lower rates of long

A new drug could help frostbite victims avoid its ravages

A fraught question for the kids of Alzheimer’s: Is it coming for us?

Abridge raises $150m as clinical notes automation market heats up

leisure time

focus

focus

entertainment